Drug Profile
BMTP 11
Alternative Names: BMTP11; Bone metastasis targeting peptide 11Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Arrowhead Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Peptides
- Mechanism of Action Interleukin 11 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer(Metastatic disease) in USA (IV, Infusion)